Welcome, Guest. Please login or register.
May 12, 2021, 01:07:57 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 759583
  • Total Topics: 64411
  • Online Today: 330
  • Online Ever: 4912
  • (November 13, 2019, 02:56:14 am)
Users Online
Users: 0
Guests: 221
Total: 221

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Experimental vaccine primes immune system to produce BNABs  (Read 249 times)

0 Members and 1 Guest are viewing this topic.

Offline Cosmicdancer

  • Member
  • Posts: 196
Experimental vaccine primes immune system to produce BNABs
« on: March 14, 2021, 11:34:49 am »
First-in-human clinical trial confirms new HIV vaccine approach
The experimental vaccine primed the immune system as the first stage in the production of broadly neutralizing antibodies (BNABs)

A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.

"This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well," says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center, whose laboratory developed the vaccine. "With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens."

Schief presented the results on behalf of the study team at the International AIDS Society HIV Research for Prevention (HIVR4P) virtual conference today.

The study sets the stage for additional clinical trials that will seek to refine and extend the approach -- with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.

HIV, which affects more than 38 million people globally, is known to be among the most difficult viruses to target with a vaccine, in large part because it constantly evolves into different strains to evade the immune system.

"These exciting findings emerge from remarkably creative, innovative science and are a testament to the research team's talent, dedication and collaborative spirit, and to the generosity of the trial participants," says Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. "Given the urgent need for an HIV vaccine to rein in the global epidemic, we think these results will have broad implications for HIV vaccine researchers as they decide which scientific directions to pursue. The collaboration among individuals and institutions that made this important and exceptionally complex clinical trial so successful will be tremendously enabling to accelerate future HIV vaccine research."

The full article is here
https://www.sciencedaily.com/releases/2021/02/210203162249.htm
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
2/2008 - 5/2015 - undetectable on Atripla
May, 2015 - UD, switched to Complera
September, 2015 - UD, 980 cd4, switched to Stribild (Complera interacted with acid reflux medication)
January, 2016 - Stribild, UD, 950 cd4
June, 2016 - UD, 929 cd4

 


Terms of Membership for these forums
 

© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.